Intelligyn
AI-Driven clinical decision support for enhanced Ovarian Cancer detection through Deep Learning on Ultrasound Images.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | SEK384k | Grant | |
| Total Funding | 000k | ||
| SEK | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | - | 33 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | - | (86 %) | (68 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Intelligyn.ai specializes in AI-driven clinical decision support systems aimed at enhancing the detection of ovarian cancer. The company leverages deep learning technology to analyze ultrasound images, providing real-time feedback during exams. This approach addresses the shortage of specialized practitioners by bridging expertise gaps, ensuring accurate diagnoses, and reducing unnecessary surgeries. Intelligyn.ai operates in the healthcare sector, focusing on gynecological care, and serves medical professionals and healthcare institutions. The business model revolves around offering a cloud-based platform that is vendor and platform neutral, fostering advanced diagnostics. Although its AI capabilities are not yet approved for sale and distribution, the company is positioned to make a significant economic impact by enhancing patient outcomes, reducing treatment costs, and streamlining healthcare expenses. Keywords: AI, ovarian cancer, ultrasound, deep learning, healthcare, diagnostics, gynecology, cloud platform, real-time feedback, expertise gap.